Author:
Bell Jill A.,Galaznik Aaron,Blazer Marlo,Shih Huai-Che,Farrelly Eileen,Ogbonnaya Augustina,Eaddy Michael,Fram Robert J.,Faller Douglas V.
Funder
Takeda Pharmaceuticals U.S.A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference18 articles.
1. Komrokji RS. Current state of the art: management of higher risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2016;16(S1):S39–43.
2. Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272–81.
3. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.
4. National Comprehensive Cancer Network. Myelodysplastic syndromes. V.1.2018. Fort Washington.
https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
. Accessed 4 October 2017.
5. Powers A, Faria C, Broder MS, et al. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits. 2012;5(7):455–65.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献